This site is intended for health professionals only

Cisplatin tops carboplatin against NSCLC?

teaser

Cisplatin provides a higher response rate compared with carboplatin when used to treat nonsmall-cell lung cancer (NSCLC), particularly for earlier-stage disease and for patients with advanced disease but good prognosis.

Such are the results of a study published in the Journal of the National Cancer Institute, which noted that platinum-based chemotherapy leads to a small but statistically significant improvement in survival in patients with advanced NSCLC, compared to best supportive care, or when added to a number of single agents (eg, gemcitabine, taxanes, vinorelbine).

Although carboplatin has largely replaced cisplatin as the platinum drug of choice due to its association with a lower incidence of serious side-effects (eg, neurotoxicity, nephrotoxicity), it is not known whether the two drugs have similar clinical efficacy. Researchers therefore performed an individual patient data meta-analysis comparing carboplatin and cisplatin in treating advanced NSCLC.

Nine randomised trials (n=2,968) comparing carboplatin (n=1,479) with cisplatin (n=1,489) in first-line treatment of advanced (stage IIIB–IV) NSCLC were identified and included in the analysis. Primary endpoint was overall survival (OS); secondary endpoints included overall response rate (ORR) and toxicity. All analyses were carried out according to the intention-to-treat principle.

The main results for an overall median follow-up of 1,021 days were:

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

• Cisplatin-treated patients had a median OS of 9.1 months and a one-year survival probability of 37%; the respective figures for carboplatin-treated patients were 8.4 months and 34% (HR for risk of death with carboplatin = 1.07, 95% CI = 0.99–1.15, p=NS). However, there was statistically significant heterogeneity between treatment effects on mortality among the trials.

• Subgroup analyses found carboplatin-based chemotherapy was associated with a statistically significant increase in mortality in patients with nonsquamous tumours (HR = 1.12; 95% CI = 1.01–1.23) and in those treated with third-generation chemotherapy (HR = 1.11; 95% CI = 1.01–1.21).

• ORR was higher for patients treated with cisplatin than for patients treated with carboplatin (30% versus 24%, respectively; OR = 1.37; 95% CI = 1.16–1.61; p<0.001).

• Cisplatin-based chemotherapy caused more nausea and vomiting (OR = 0.42, 95% CI = 0.33–0.53, p<0.001) and renal toxicity (OR = 0.37, 95% CI = 0.15–0.88, 9=0.018), whereas carboplatin-based therapy resulted in a higher incidence of thrombocytopenia (OR = 2.27, 95% CI = 1.71–3.01, p<0.001). The incidence of neurotoxicity, leucopenia, neutropenia and anaemia did not differ between the two groups.

The authors conclude: “Based on the results of the randomised trials conducted thus far, our individual patient data meta-analysis, as well as the previous literature-based meta-analyses, cisplatin should remain the reference platinum agent for treatment of NSCLC, at least in advanced-disease patients with good prognosis and in those with earlier-stage disease”.

J Natl Cancer Inst 2007;99:828-9,847-57.

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x